SAN FRANCISCO, June 27, 2023 /PRNewswire/ -- SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced the expansion of its leadership team with the appointment of Carolyne Zimmermann as its Chief Business Officer. Zimmermann brings more than 20 years of experience in leading innovative business development transactions with senior executive roles at Johnson & Johnson and Novartis and 4D Molecular Therapeutics.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced completion of its $60.75M Series A financing round. The financing will support the continued development of SonoThera’s ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.